Cargando…

Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target

Obesity-related glomerulopathy (ORG) is a secondary glomerular disease caused by obesity, with clinical manifestations such as proteinuria and glomerulomegaly. Currently, the high incidence of obesity brings a change in the spectrum of kidney diseases across the globe, including China. ORG has becom...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Lifang, Li, Ye, Yu, Yue, Xu, Minmin, Chen, Huilan, Li, Lijie, Peng, Ting, Zhao, Kang, Zhuang, Yongze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560069/
https://www.ncbi.nlm.nih.gov/pubmed/34737593
http://dx.doi.org/10.2147/DMSO.S334199
_version_ 1784592870544506880
author Wei, Lifang
Li, Ye
Yu, Yue
Xu, Minmin
Chen, Huilan
Li, Lijie
Peng, Ting
Zhao, Kang
Zhuang, Yongze
author_facet Wei, Lifang
Li, Ye
Yu, Yue
Xu, Minmin
Chen, Huilan
Li, Lijie
Peng, Ting
Zhao, Kang
Zhuang, Yongze
author_sort Wei, Lifang
collection PubMed
description Obesity-related glomerulopathy (ORG) is a secondary glomerular disease caused by obesity, with clinical manifestations such as proteinuria and glomerulomegaly. Currently, the high incidence of obesity brings a change in the spectrum of kidney diseases across the globe, including China. ORG has become another important secondary nephropathy leading to end-stage renal disease (ESRD), and its incidence has increased significantly. This trend is bound to bring about a serious socioeconomic burden. Therefore, it is urgent to study its pathogenesis and intervention measures. Currently, the occurrence and development mechanisms in ORG are complicated by many factors, which are still unclear. In the past 20 years, with the continuous intensive research on mechanisms such as hypoxia in the metabolic process, immune inflammation, and pyroptosis, there have been new advances in the mechanism of ORG, especially the important role of inflammation in podocyte injury and its impact on the progress of ORG. Here, we briefly review the possible pathogenic role of the inflammasome in the podocyte damage in ORG and summarize the possible therapeutical strategies targeting inflammasome.
format Online
Article
Text
id pubmed-8560069
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85600692021-11-03 Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target Wei, Lifang Li, Ye Yu, Yue Xu, Minmin Chen, Huilan Li, Lijie Peng, Ting Zhao, Kang Zhuang, Yongze Diabetes Metab Syndr Obes Review Obesity-related glomerulopathy (ORG) is a secondary glomerular disease caused by obesity, with clinical manifestations such as proteinuria and glomerulomegaly. Currently, the high incidence of obesity brings a change in the spectrum of kidney diseases across the globe, including China. ORG has become another important secondary nephropathy leading to end-stage renal disease (ESRD), and its incidence has increased significantly. This trend is bound to bring about a serious socioeconomic burden. Therefore, it is urgent to study its pathogenesis and intervention measures. Currently, the occurrence and development mechanisms in ORG are complicated by many factors, which are still unclear. In the past 20 years, with the continuous intensive research on mechanisms such as hypoxia in the metabolic process, immune inflammation, and pyroptosis, there have been new advances in the mechanism of ORG, especially the important role of inflammation in podocyte injury and its impact on the progress of ORG. Here, we briefly review the possible pathogenic role of the inflammasome in the podocyte damage in ORG and summarize the possible therapeutical strategies targeting inflammasome. Dove 2021-10-28 /pmc/articles/PMC8560069/ /pubmed/34737593 http://dx.doi.org/10.2147/DMSO.S334199 Text en © 2021 Wei et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Wei, Lifang
Li, Ye
Yu, Yue
Xu, Minmin
Chen, Huilan
Li, Lijie
Peng, Ting
Zhao, Kang
Zhuang, Yongze
Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target
title Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target
title_full Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target
title_fullStr Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target
title_full_unstemmed Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target
title_short Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target
title_sort obesity-related glomerulopathy: from mechanism to therapeutic target
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560069/
https://www.ncbi.nlm.nih.gov/pubmed/34737593
http://dx.doi.org/10.2147/DMSO.S334199
work_keys_str_mv AT weilifang obesityrelatedglomerulopathyfrommechanismtotherapeutictarget
AT liye obesityrelatedglomerulopathyfrommechanismtotherapeutictarget
AT yuyue obesityrelatedglomerulopathyfrommechanismtotherapeutictarget
AT xuminmin obesityrelatedglomerulopathyfrommechanismtotherapeutictarget
AT chenhuilan obesityrelatedglomerulopathyfrommechanismtotherapeutictarget
AT lilijie obesityrelatedglomerulopathyfrommechanismtotherapeutictarget
AT pengting obesityrelatedglomerulopathyfrommechanismtotherapeutictarget
AT zhaokang obesityrelatedglomerulopathyfrommechanismtotherapeutictarget
AT zhuangyongze obesityrelatedglomerulopathyfrommechanismtotherapeutictarget